Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
0.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Adial Pharmaceuticals, Inc.
Market Cap
$11.50M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$11.47M
Gross Margin
14.12%
TTM Avg
57.06%
3Y Avg
28.53%
5Y Avg
19.02%
Market Cap
$11.23M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
-4489.78%
Market Cap
$11.81M
Gross Margin
71.61%
TTM Avg
70.70%
3Y Avg
67.95%
5Y Avg
69.37%
Market Cap
$10.91M
Gross Margin
89.58%
TTM Avg
88.41%
3Y Avg
-34.57%
5Y Avg
-154.89%
Market Cap
$12.12M
Gross Margin
36.23%
TTM Avg
36.65%
3Y Avg
39.59%
5Y Avg
41.13%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adial Pharmaceuticals, Inc. (ADIL) | $11.50M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.47M | 14.12% | 57.06% | 28.53% | 19.02% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.23M | 0.00% | 50.00% | 25.00% | -4489.78% |
| Cytosorbents Corporation (CTSO)vs › | $11.81M | 71.61% | 70.70% | 67.95% | 69.37% |
| Lantern Pharma Inc. (LTRN)vs › | $11.83M | 0.00% | 0.00% | 0.00% | 0.00% |
| BioVie Inc. (BIVI)vs › | $11.12M | 0.00% | 0.00% | 0.00% | 0.00% |
| Biofrontera Inc. (BFRI)vs › | $11.11M | 84.45% | 64.39% | 56.15% | 53.94% |
| Cerenome, Inc. (CNSY)vs › | $10.91M | 89.58% | 88.41% | -34.57% | -154.89% |
| IRIDEX Corporation (IRIX)vs › | $12.12M | 36.23% | 36.65% | 39.59% | 41.13% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.83M | N/A | -101.19% | -33.23% | -22.16% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
